JP5898615B2 - ヘプシジンの吸着用の吸着剤 - Google Patents
ヘプシジンの吸着用の吸着剤 Download PDFInfo
- Publication number
- JP5898615B2 JP5898615B2 JP2012520933A JP2012520933A JP5898615B2 JP 5898615 B2 JP5898615 B2 JP 5898615B2 JP 2012520933 A JP2012520933 A JP 2012520933A JP 2012520933 A JP2012520933 A JP 2012520933A JP 5898615 B2 JP5898615 B2 JP 5898615B2
- Authority
- JP
- Japan
- Prior art keywords
- line
- patient
- hepcidin
- medical device
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 title claims description 46
- 102000018511 hepcidin Human genes 0.000 title claims description 40
- 108060003558 hepcidin Proteins 0.000 title claims description 40
- 229940066919 hepcidin Drugs 0.000 title claims description 40
- 239000003463 adsorbent Substances 0.000 title claims description 33
- 238000001179 sorption measurement Methods 0.000 title description 7
- 210000004369 blood Anatomy 0.000 claims description 27
- 239000008280 blood Substances 0.000 claims description 27
- 239000011148 porous material Substances 0.000 claims description 25
- 239000012530 fluid Substances 0.000 claims description 19
- 210000001124 body fluid Anatomy 0.000 claims description 17
- 239000002245 particle Substances 0.000 claims description 15
- 239000003446 ligand Substances 0.000 claims description 14
- 239000011159 matrix material Substances 0.000 claims description 10
- 239000010839 body fluid Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- 238000010494 dissociation reaction Methods 0.000 claims description 5
- 230000005593 dissociations Effects 0.000 claims description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 230000000779 depleting effect Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229920000620 organic polymer Polymers 0.000 claims description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 28
- 229910052742 iron Inorganic materials 0.000 description 14
- 238000000034 method Methods 0.000 description 11
- 239000007790 solid phase Substances 0.000 description 10
- 210000000601 blood cell Anatomy 0.000 description 9
- 208000007502 anemia Diseases 0.000 description 8
- 208000020832 chronic kidney disease Diseases 0.000 description 7
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 7
- 229910052753 mercury Inorganic materials 0.000 description 7
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 6
- 101800003310 Hepcidin-25 Proteins 0.000 description 6
- 102400001151 Hepcidin-25 Human genes 0.000 description 6
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 6
- 238000001631 haemodialysis Methods 0.000 description 6
- 230000000322 hemodialysis Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000012876 carrier material Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 2
- 108091006976 SLC40A1 Proteins 0.000 description 2
- 238000009175 antibody therapy Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 201000000361 Hemochromatosis type 2 Diseases 0.000 description 1
- 101800003308 Hepcidin-20 Proteins 0.000 description 1
- 102400001150 Hepcidin-20 Human genes 0.000 description 1
- 101001021253 Homo sapiens Hepcidin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- -1 acryl Chemical group 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 238000002459 porosimetry Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
- B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
- B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3268—Macromolecular compounds
- B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
- B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- External Artificial Organs (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102009034150A DE102009034150A1 (de) | 2009-07-20 | 2009-07-20 | Adsorbens zur Adsorption von Hepcidin |
| DE102009034150.1 | 2009-07-20 | ||
| PCT/EP2010/004303 WO2011009555A1 (de) | 2009-07-20 | 2010-07-15 | Adsorbens zur adsorption von hepcidin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012533582A JP2012533582A (ja) | 2012-12-27 |
| JP2012533582A5 JP2012533582A5 (enExample) | 2013-08-29 |
| JP5898615B2 true JP5898615B2 (ja) | 2016-04-06 |
Family
ID=42797095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520933A Expired - Fee Related JP5898615B2 (ja) | 2009-07-20 | 2010-07-15 | ヘプシジンの吸着用の吸着剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8915875B2 (enExample) |
| EP (1) | EP2457097B1 (enExample) |
| JP (1) | JP5898615B2 (enExample) |
| CN (1) | CN102549439B (enExample) |
| DE (1) | DE102009034150A1 (enExample) |
| WO (1) | WO2011009555A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2633053A1 (en) * | 2010-10-29 | 2013-09-04 | Noxxon Pharma AG | Use of hepcidin binding nucleic acids for depletion of hepcidin from the body |
| SE1200356A1 (sv) * | 2011-10-30 | 2013-05-01 | Kurt Nilsson | Polymerbaserad produkt och användning |
| DE102012025164A1 (de) | 2012-12-21 | 2014-06-26 | Fresenius Medical Care Deutschland Gmbh | Vorrichtung zur Entfernung proteingebundener Toxine aus Blutplasma |
| US9585996B2 (en) * | 2014-04-02 | 2017-03-07 | Human Biomed, Inc. | Blood purifying filter and blood purifying apparatus |
| US11904082B2 (en) | 2016-08-01 | 2024-02-20 | Kaneka Corporation | Adsorbent for calciprotein particles, adsorption removal system, and method for utilization thereof |
| EP3735281B1 (en) | 2018-01-05 | 2024-11-27 | Path Ex, Inc. | Device for the capture and removal of disease material from fluids |
| US20190247560A1 (en) * | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
| EP3946054A4 (en) * | 2019-03-26 | 2022-12-28 | Seer, Inc. | COMPOSITIONS, METHODS AND SYSTEMS FOR PROTEIN CORONA ANALYSIS FROM BIOLIQUIDS AND THEIR USES |
| KR20220088699A (ko) | 2019-09-27 | 2022-06-28 | 디스크 메디슨, 인크. | 골수섬유증 및 관련 상태의 치료 방법 |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56145858A (en) * | 1980-04-15 | 1981-11-12 | Unitika Ltd | Purifier for body fluid |
| JPS5897366A (ja) * | 1981-12-08 | 1983-06-09 | 旭化成株式会社 | 血液及び体液物質の除去装置 |
| CN1019132B (zh) * | 1985-03-29 | 1992-11-18 | 格鲁波莱佩蒂特公司 | 抗尿激酶单克隆抗体，带有它的基质，其试验方法和使用它的生化试验药盒 |
| DE3932971C2 (de) | 1989-10-03 | 2003-03-13 | Fresenius Ag | Zur Eliminierung von Biomakromolekülen, insbesondere LDL und Endotoxinen, aus Vollblut in extrakorporalem Kreislauf geeignetes Adsorbens |
| US5476715A (en) | 1989-10-03 | 1995-12-19 | Fresenius Ag | Particulate adsorbent for the removal of biomacromolecules such as LDL and endotoxins from whole blood in extracorporeal circuits |
| US6416487B1 (en) * | 1997-07-30 | 2002-07-09 | Renal Tech International Llc | Method of removing beta-2 microglobulin from blood |
| DE19913707A1 (de) | 1999-03-26 | 2000-10-05 | Privates Inst Bioserv Gmbh | Immunadsorber zur Sepsistherapie |
| CA2448382C (en) | 2001-05-25 | 2013-02-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of hepcidin as a regulator of iron homeostasis |
| CN1116926C (zh) * | 2001-09-21 | 2003-08-06 | 大连理工大学 | 用于治疗高胆红素血症的免疫吸附材料 |
| SE0201257D0 (sv) | 2002-04-25 | 2002-04-25 | Medical Invest In Sweden Ab | Improved Separation |
| CN1408442A (zh) | 2002-09-09 | 2003-04-09 | 天津医科大学总医院 | 全血灌流吸附治疗用吸附剂 |
| EP1578254B1 (en) * | 2002-11-19 | 2013-03-06 | DRG International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor |
| US8017737B2 (en) * | 2002-11-19 | 2011-09-13 | Hasan Kulaksiz | Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor |
| DE10324668A1 (de) * | 2003-05-30 | 2004-12-23 | Fresenius Medical Care Deutschland Gmbh | Vorrichtung zur extrakorporalen Bestrahlung einer Bilirubin enthaltenden Flüssigkeit und Verfahren hierfür |
| WO2006042507A1 (de) | 2004-10-20 | 2006-04-27 | Adexter Technology Limited | Immunadsorber für die behandlung von entzündungen |
| PE20090722A1 (es) * | 2007-02-02 | 2009-07-13 | Amgen Inc | Hepcidina, antagonistas de la hepcidina y metodos de uso |
| ATE553778T1 (de) | 2007-10-02 | 2012-05-15 | Inst Nat Sante Rech Med | Für humanes hepcidin spezifische antikörper |
| AR069062A1 (es) * | 2007-11-02 | 2009-12-23 | Lilly Co Eli | Anticuerpo anti-hepcidina |
| CN101279242A (zh) | 2008-05-20 | 2008-10-08 | 大连理工大学 | 用于抗体清除的血液净化吸附剂 |
-
2009
- 2009-07-20 DE DE102009034150A patent/DE102009034150A1/de not_active Ceased
-
2010
- 2010-07-15 JP JP2012520933A patent/JP5898615B2/ja not_active Expired - Fee Related
- 2010-07-15 WO PCT/EP2010/004303 patent/WO2011009555A1/de not_active Ceased
- 2010-07-15 US US13/321,329 patent/US8915875B2/en active Active
- 2010-07-15 CN CN201080032425.0A patent/CN102549439B/zh not_active Expired - Fee Related
- 2010-07-15 EP EP10735203.1A patent/EP2457097B1/de not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| EP2457097B1 (de) | 2015-09-09 |
| EP2457097A1 (de) | 2012-05-30 |
| US20120063954A1 (en) | 2012-03-15 |
| US8915875B2 (en) | 2014-12-23 |
| JP2012533582A (ja) | 2012-12-27 |
| WO2011009555A1 (de) | 2011-01-27 |
| CN102549439A (zh) | 2012-07-04 |
| CN102549439B (zh) | 2016-01-20 |
| DE102009034150A1 (de) | 2011-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5898615B2 (ja) | ヘプシジンの吸着用の吸着剤 | |
| JP6092380B2 (ja) | 体外灌流装置 | |
| JP2012533582A5 (enExample) | ||
| JP2013518687A5 (enExample) | ||
| US10625241B2 (en) | Hemocompatible adsorber for the dialysis of protein-bound uremic toxins | |
| CA2443237C (en) | Method for eliminating potentially toxic and/or harmful substances | |
| JP5546554B2 (ja) | タンパク質結合物質を除去するための収着剤 | |
| JP4578405B2 (ja) | 全血処理が可能な低密度リポ蛋白およびフィブリノーゲンの吸着材、及び吸着器 | |
| US20020060180A1 (en) | Hemodialysis apparatus | |
| Oda et al. | Cytokine adsorptive property of various adsorbents in immunoadsorption columns and a newly developed adsorbent: an in vitro study | |
| JP2001299904A (ja) | フィブリノーゲンおよび／またはフィブリンの濃度を減少させるための吸着剤、吸着装置の製造のための吸着剤の使用、および吸着剤を有する吸着装置 | |
| US20180093032A1 (en) | Targeted apheresis using binding agents or ligands immobilized on membranes | |
| JP2022542517A (ja) | 血液中の炎症促進性サイトカインの広範囲にわたる減少のためのデバイス、システム及び方法 | |
| CN116618024B (zh) | 一种清除过量铁调素的吸附剂及其制备方法 | |
| RU2007145933A (ru) | Обедненный молекулами стабилизаторов раствор альбумина | |
| KR102601124B1 (ko) | 성분채집 컬럼의 단순화된 재생을 위한 성분채집 디바이스 | |
| JP2008206753A (ja) | 炎症性疾患処置カラム | |
| Lameire et al. | Adsorption techniques and the use of sorbents | |
| US11957825B2 (en) | Modified TNF as a capture ligand | |
| JPS6159142B2 (enExample) | ||
| JPH0550301B2 (enExample) | ||
| Kojima | High-performance immunoaffinity chromatography, an immunoaffinity membrane for selective removal of plasma components, and safety evaluation of the latter system | |
| JPS6353827B2 (enExample) | ||
| Levine | Extracorporeal removal of plasma hemoglobin in sepsis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130712 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130712 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141117 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150216 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150316 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150327 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150909 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151211 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20151221 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160208 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160304 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5898615 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |